Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.86 |
| ▸ | CSF1R | P07333 | 1/20 | 0.76 |
| ▸ | KDR | P35968 | 2/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.72 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.72 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.72 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.72 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.72 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.72 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766235 | 1.00 | EGFR (0.86) | EGFRCSF1RKDRHDAC3HDAC4 | |
| SCHEMBL7499430 | 1.00 | EGFR (0.86) | EGFRCSF1RKDRHDAC3HDAC4 | |
| SCHEMBL12308303 | 0.91 | EGFR (0.86) | EGFRCSF1RKDRHDAC3HDAC4 | |
| Pki-166 SCHEMBL185822 | 0.89 | EGFR (1.00) | EGFRCSF1RKDRHDAC3HDAC4 | |
| Pki-166 SCHEMBL29352405 | 0.89 | EGFR (1.00) | EGFRCSF1RKDRHDAC3HDAC4 | |
| SCHEMBL4806301 | 0.89 | EGFR (0.84) | EGFRCSF1RKDRHDAC3HDAC4 | |
| Pki-166 SCHEMBL9973098 | 0.89 | EGFR (1.00) | EGFRCSF1RKDRHDAC3HDAC4 | |
| Pki-166 SCHEMBL209560 | 0.89 | EGFR (1.00) | EGFRCSF1RKDRHDAC3HDAC4 | |
| Pki-166 SCHEMBL30883827 | 0.89 | EGFR (1.00) | EGFRCSF1RKDRHDAC3HDAC4 | |
| SCHEMBL4767020 | 0.88 | EGFR (0.82) | EGFRCSF1RKDRHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0836605-B1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2002-02-06 | — | — | EP | claimed |
| EP-0836605-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1998-04-22 | — | — | EP | claimed |
| WO-1997002266-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1997-01-23 | — | — | WO | claimed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080161320-A1 | FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-07-03 | — | — | US | disclosed |
| EP-0938486-B1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| CN-1100778-C | Pyrrolopyrimidines and process for their preparation | NOVARTIS CO (CH) | 2003-02-05 | — | — | CN | disclosed |
| EP-0836605-B1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2002-02-06 | — | — | EP | disclosed |
| US-6180636-B1 | USED TO INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR THE EPIDERMAL GROWTH FACTOR AND C-ERBB2 KINASE AND CAN BE USED AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2001-01-30 | — | — | US | disclosed |
| US-6140332-A | Pyrrolopyrimidines and processes for the preparation thereof | NOVARTIS AG (CH) | 2000-10-31 | — | — | US | disclosed |
| EP-0938486-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1999-09-01 | — | — | EP | disclosed |
| CN-1194647-A | Pyrrolopyrimidines and processes for preparation thereof | NOVARTIS CO (CH) | 1998-09-30 | — | — | CN | disclosed |
| EP-0836605-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1998-04-22 | — | — | EP | disclosed |
| WO-1998007726-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | disclosed |
| WO-1997002266-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | EGFR 2358/4885CSF1R 1746/4885KDR 2667/4885 |
| US-20080161320-A1 | FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | HDAC1, HDAC2, BAZ2A | EGFR 1171/4885CSF1R 2305/4885KDR 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.